-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Decline in Short Interest
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Decline in Short Interest
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a significant drop in short interest in December. As of December 30th, there was short interest totalling 15,400 shares, a drop of 34.2% from the December 15th total of 23,400 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 511,700 shares, the short-interest ratio is currently 0.0 days.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned 0.74% of Kiora Pharmaceuticals at the end of the most recent reporting period.
Get Kiora Pharmaceuticals alerts:Kiora Pharmaceuticals Stock Down 3.4 %
KPRX traded down $0.12 on Thursday, hitting $3.37. The company had a trading volume of 35,439 shares, compared to its average volume of 714,915. The company has a market cap of $3.85 million, a PE ratio of -0.06 and a beta of 0.26. Kiora Pharmaceuticals has a 12-month low of $2.32 and a 12-month high of $39.18. The business's fifty day simple moving average is $3.68 and its 200 day simple moving average is $8.35.
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($4.35) EPS for the quarter. On average, analysts anticipate that Kiora Pharmaceuticals will post -19.58 earnings per share for the current fiscal year.About Kiora Pharmaceuticals
(Get Rating)
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a significant drop in short interest in December. As of December 30th, there was short interest totalling 15,400 shares, a drop of 34.2% from the December 15th total of 23,400 shares. Approximately 1.1% of the company's shares are short sold. Based on an average trading volume of 511,700 shares, the short-interest ratio is currently 0.0 days.
基奧拉製藥公司 (NASDAQ: KPRX — 獲取評級) 在十二月看到短期利益顯著下降.截至 12 月 30 日,短期利息總額為 15,400 股,較十二月十五日總額 23,400 股股份下降了 34.2%。約 1.1% 的公司股份賣空。根據平均交易量為 511,700 股,短息比率目前為 0.0 天。
Institutional Inflows and Outflows
機構流入和流出
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 93,619 shares of the company's stock, valued at approximately $58,000. Renaissance Technologies LLC owned 0.74% of Kiora Pharmaceuticals at the end of the most recent reporting period.
對沖基金最近購買了 Kiora 製藥股票的新股份。文藝復興技術有限責任公司在第一季度購買了基奧拉製藥公司(NASDAQ:KPRX-獲得評級)的股份的新股份,根據該公司在最近的 13F 與證券交易委員會(SEC)提交的文件。該基金買入了該公司股票 93,619 股,價值約 58,000 美元。文藝復興技術有限責任公司擁有 0.74% 基奧拉製藥在最近的報告期結束.
Kiora Pharmaceuticals Stock Down 3.4 %
基奧拉製藥庫存下降 3.4%
KPRX traded down $0.12 on Thursday, hitting $3.37. The company had a trading volume of 35,439 shares, compared to its average volume of 714,915. The company has a market cap of $3.85 million, a PE ratio of -0.06 and a beta of 0.26. Kiora Pharmaceuticals has a 12-month low of $2.32 and a 12-month high of $39.18. The business's fifty day simple moving average is $3.68 and its 200 day simple moving average is $8.35.
KPRX 週四交易下跌 0.12 美元,觸及 3.37 美元。該公司的交易量為 35,439 股,而其平均交易量為 714,915 股。該公司的市值為 385 萬美元,私募股權比率為 -0.06,貝塔值為 0.26。基奧拉製藥有 12 個月低點 2.32 美元和 12 個月高點 39.18 美元。該企業的五十天簡單移動平均線為 3.68 美元,其 200 天簡單移動平均線為 8.35 美元。
About Kiora Pharmaceuticals
關於奇奧拉製藥
(Get Rating)
(取得評分)
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Kiora Pharicies 是一家臨床階段專業製藥公司,在美國開發和商業化治療眼科疾病的療法。其主導產品是 KIO-301,這是一種潛在的視力恢復小分子,正在進行 1 期臨床試驗,可作為光開關,以恢復遺傳性和與年齡相關的退行性視網膜疾病患者的視力。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Kiora Pharmaceuticals (KPRX)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 獲取有關基奧拉製藥(KPRX)的研究報告的免費副本
- 高股息收益的必和必拓認為中國推動 23 年增長
- Airbnb 是否正在設置上漲 38%,正如分析師的預測?
- 特斯拉車輛的降價是否意味著 TSLA 股票相同?
- 微軟裁員信號裁員為其他科技公司?
- 快速購買緊固件的不止一個理由
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Kiora 製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Kiora 製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧